IDBS Unveils IDBS Polar Control: Revolutionizing Process Management in BioPharmaceutical Development

WOKING, United Kingdom, March 7, 2025 /PRNewswire/ — IDBS, a leading global provider of cloud software for BioPharma companies, is excited to announce the launch of IDBS Polar Control, a groundbreaking module within the Polar platform, designed to transform process management in BioPharmaceutical development. The official launch will take place at two prestigious events, taking place next week, the Lab of the Future Congress in Boston and the Biologics Manufacturing Asia (BMA) Pre-conference Seminar in Singapore.

Polar Control is set to redefine how BioPharmaceutical companies manage and evolve their processes. This innovative module allows users to create and manage detailed versions of their individual parameters, and broader process definitions, assigning and monitoring parameter criticality and their specifications. By categorizing the criticality of individual parameters, maintaining a comprehensive version history, and establishing connectivity with experiments and results, Polar Control provides unparalleled insight into the evolution of processes over time.

“Polar Control addresses a significant gap in digital process management,” said Pietro Forgione, General Manager at IDBS. “Our solution offers a centralized knowledge repository for parameter tracking, seamlessly connecting to process execution. This not only accelerates drug development, technology transfer but also reduces the need for repetitive experiments, ultimately speeding up time to market.”

Key features of Polar Control include:

• Granular parameter management: Track and manage individual process parameters with precision, ensuring optimal conditions are maintained throughout development.
   
• Comprehensive version history: Maintain a detailed history of changes to process parameters, allowing for better understanding and control over process evolution.
   
• Enhanced process understanding: By accurately recording process data, Polar Control helps reduce future study time and improve process efficiency.
   
• Facilitated technology transfer: The module streamlines technology transfer by offering a clear and detailed record of process parameters and their evolution, making it easier to replicate and transfer processes between teams and facilities with accurate process knowledge.

The launch of Polar Control is part of IDBS’ ongoing commitment to providing cutting-edge solutions that drive digital maturity in the BioPharmaceutical Industry. With this new module, IDBS aims to support late-stage development and CDMO organizations, as well as prospects transitioning from non-GxP to GxP environments.

Join us at the Lab of the Future Congress in Boston and the BMA Pre-conference Seminar in Singapore to learn more about how Polar Control can revolutionize your process management strategy.

For more information, visit Polar Control.

About IDBS

IDBS helps BioPharma organizations unlock the potential of AI/ML to improve the lives of patients. As a trusted long-term partner to 80% of the top 20 global BioPharma companies¹, IDBS delivers powerful cloud software and services specifically designed to meet the evolving needs of the BioPharma sector.

IDBS, a Danaher company, leverages 35 years of scientific informatics expertise to help organizations design, execute and orchestrate processes, manage, contextualize and structure data and gain valuable insights throughout the product lifecycle, from R&D through manufacturing. Known for its signature IDBS E-WorkBook software, IDBS has extended its flexible, scalable solutions to the IDBS Polar and PIMS cloud platforms to help scientists make smarter decisions with assured confidence in both GxP and non-GxP environments. 

Visit idbs.com, to learn more about IDBS.

1. Rank measured by Market Cap, Q1 2024.

MEDIA ENQUIRIES
 e | mediaenquiries@idbs.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/idbs-unveils-idbs-polar-control-revolutionizing-process-management-in-biopharmaceutical-development-302395809.html

SOURCE IDBS